Effects of SLC34A3 or SLC34A1 variants on calcium and phosphorus homeostasis

• Published in: Pediatric nephrology (Berlin, West) West), 2025, Vol.40 (1), p.117-129
• Main Authors: Naciri Bennani, Hamza, Chtioui, Imane, Allirot, Camille, Somrani, Rim, Jouve, Thomas, Rostaing, Lionel, Bourdat-Michel, Guylhene
• Format: Article
• Language: English
• Subjects: Azoles; Calcinosis; Calcium - metabolism; Calcium homeostasis; Child; Child, Preschool; Diagnosis; Dietary intake; Dietary supplements; Female; Fluconazole; Genes; Homeostasis; Humans; Hygiene; Hypercalciuria; Hypercalciuria - genetics; Hypophosphatemia; Hypophosphatemia - etiology; Hypophosphatemia - genetics; Infant; Kidney diseases; Male; Medicine; Medicine & Public Health; Nephrocalcinosis - genetics; Nephrolithiasis; Nephrology; Nutrient deficiency; Original Article; Patients; Pediatrics; Phenotypes; Phosphorus - blood; Phosphorus - metabolism; Retrospective Studies; Sodium-Phosphate Cotransporter Proteins, Type II - genetics; Sodium-Phosphate Cotransporter Proteins, Type IIa; Sodium-Phosphate Cotransporter Proteins, Type IIc; Thiazides; Urology
• ISSN: 0931-041X; 1432-198X; 1432-198X
• DOI: 10.1007/s00467-024-06505-3

Background Variants in SLC34A1 and SLC34A2 genes, which encode co-transporters NaPi2a and NaPi2c, respectively, can lead to hypophosphatemia due to renal phosphate loss. This condition results in hypercalcitriolemia and hypercalciuria, leading to formation of kidney stones and nephrocalcinosis. Phenotype is highly variable. Management includes hyperhydration, dietary modifications, and/or phosphate supplementation. Thiazides and azoles may be used, but randomized studies are needed to confirm their clinical efficacy. Methods We conducted a retrospective study in the pediatric nephrology unit at Grenoble University Hospital from January 2010 to December 2023. The study aimed to describe clinical and biological symptoms of patients with confirmed SLC34A1 and SLC34A3 gene variants and their outcomes. Results A total of 11 patients (9 females) from 6 different families had variants in the SLC34A1 (5 patients) and SLC34A3 (6 patients) genes. Median age at diagnosis was 72 [1–108] months. Average follow-up duration was 8.1 ± 4.5 years. Presenting symptom was nephrocalcinosis (4 cases), followed by renal colic (3 cases). At diagnosis, 90% of patients had hypercalciuria and 45% had hypercalcitriolemia. Management included hyperhydration and dietary advice. All patients showed favorable outcomes with normal growth and school attendance. One patient with an SLC34A3 variant showed regression of nephrocalcinosis. Kidney function remained normal. Conclusion Clinical and biological manifestations of SLC34 gene variants are highly variable, even among siblings; therefore, management must be personalized. Hygienic and dietary measures (such as hyperhydration, a low sodium diet, and age-appropriate calcium intake) result in favorable outcomes in most cases. Use of azoles (e.g., fluconazole) appears to be a promising therapeutic option. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information